IM
Last reporting period 30 Sep, 2023
Updated —
Last price
—
Market cap $B
8.726
Exchange
XNAS - Nasdaq
-22 %
Last period ROE
662%
ROE has increased in 5 years
What is ROE ?
The return on equity ratio shows how much net profit a company earns per unit of equity. To calculate the company's rating, the return on equity adjusted for the average level of financial leverage for 3 years is taken into account. The value of 20% is the benchmark for Eyestock Rating calculation.
See also ImmunoGen
Company Analysis
IMGN valuation, rating, competitors, insights and company profile
Eyestock Rating
IMGN financial analysis by Eyestock methodology
Valuation
IMGN valuation using historical relative method
Statements
IMGN Income Statements, Balance Sheet and Cash Flow Statements
Dividends
IMGN dividend yield and annual dividend
The return on equity ratio shows how much net profit a company earns per unit of equity. To calculate the company's rating, the return on equity adjusted for the average level of financial leverage for 3 years is taken into account. The value of 20% is the benchmark for Eyestock Rating calculation.
ImmunoGen`s ROE for the last twelve months ended 2023-09-30 is -22 %
